Noninvasive profiling of serum cytokines in breast cancer patients and clinicopathological characteristics

References

• Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–998. doi:10.1038/ni1102-991.
   PubMed Web of Science ®Google Scholar
• Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, Johnston J, Madden K, Xu W, West J, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature. 2000;408:57–63. doi:10.1038/35040504.
   PubMed Web of Science ®Google Scholar
• Tan JT, Dudl E, LeRoy E, Murray R, Sprent J, Weinberg KI, Surh CD. IL-7 is critical for homeostatic proliferation and survival of naive T cells. Proc Natl Acad Sci U S A. 2001;98:8732–8737. Epub 2001 Jul 10.. doi:10.1073/pnas.161126098.
   Google Scholar
• Zou L, Barnett B, Safah H, Larussa VF, Evdemon-Hogan M, Mottram P, Wei S, David O, Curiel TJ, Zou W. Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res. 2004;64:8451–8455. doi:10.1158/0008-5472.CAN-04-1987.
   PubMed Web of Science ®Google Scholar
• Js P, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27:1160–1167. doi:10.1200/JCO.2008.18.1370.
   PubMed Web of Science ®Google Scholar
• Pruneri G, Vingiani A, Denkert C. Tumor infiltrating lymphocytes in early breast cancer. Breast. 2018;37:207–214. doi:10.1016/j.breast.2017.03.010.
   PubMed Web of Science ®Google Scholar
• Espinoza JA, Jabeen S, Batra R, Papaleo E, Haakensen V, Timmermans Wielenga V, Møller Talman M-L, Brunner N, Børresen-Dale A-L, Gromov P, et al. Cytokine profiling of tumor interstitial fluid of the breast and its relationship with lymphocyte infiltration and clinicopathological characteristics. Oncoimmunology. 2016;5:e1248015. doi:10.1080/2162402X.2016.1248015.
   PubMed Web of Science ®Google Scholar
• Naume B, Zhao X, Synnestvedt M, Borgen E, Russnes HG, Lingjaerde OC, Strømberg M, Wiedswang G, Kvalheim G, Kåresen R, et al. Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer. Mol Oncol. 2007;1:160–171. doi:10.1016/j.molonc.2007.03.004.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. doi:10.1038/nature07205.
   PubMed Web of Science ®Google Scholar
• West NR, McCuaig S, Franchini F, Powrie F. Emerging cytokine networks in colorectal cancer. Nat Rev Immunol. 2015;15:615–629. doi:10.1038/nri3896.
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013;14:7. doi:10.1186/1471-2105-14-7.
   PubMed Web of Science ®Google Scholar
• Chen K, Kolls JK. Interluekin-17A (IL17A). Gene. 2017;614:8–14. doi:10.1016/j.gene.2017.01.016.
   PubMed Web of Science ®Google Scholar
• Papadopoulos N, Lennartsson J. The PDGF/PDGFR pathway as a drug target. Mol Aspects Med. 2018;62:75-88. doi: 10.1016/j.mam.2017.11.007. Epub 2017 Nov 15.
   Web of Science ®Google Scholar
• Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi:10.1038/35021093.
   PubMed Web of Science ®Google Scholar
• Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, et al. miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors. PLoS One. 2011;6:e16915. doi:10.1371/journal.pone.0016915.
   PubMedGoogle Scholar
• Datta D, Flaxenburg JA, Laxmanan S, Geehan C, Grimm M, Waaga-Gasser AM, Briscoe DM, Pal S. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res. 2006;66:9509–9518. doi:10.1158/0008-5472.CAN-05-4345.
   PubMed Web of Science ®Google Scholar
• Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486:346–352. doi:10.1038/nature10983.
   PubMed Web of Science ®Google Scholar
• Aran D, Hu Z, Butte AJ. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017;18:220. doi:10.1186/s13059-017-1349-1.
   PubMed Web of Science ®Google Scholar
• Blankenstein T, Coulie PG, Gilboa E, Jaffee EM. The determinants of tumour immunogenicity. Nat Rev Cancer. 2012;12:307–313. doi:10.1038/nrc3246.
   PubMed Web of Science ®Google Scholar
• Ali HR, Chlon L, Pharoah PD, Markowetz F, Caldas C, Ladanyi M. Patterns of immune infiltration in breast cancer and their clinical implications: a gene-expression-based retrospective study. PLoS Med. 2016;13:e1002194. doi:10.1371/journal.pmed.1002194.
   PubMed Web of Science ®Google Scholar
• Dannenfelser R, Nome M, Tahiri A, Ursini-Siegel J, Vollan HKM, Haakensen VD, Helland Å, Naume B, Caldas C, Børresen-Dale A-L, et al. Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget. 2017;8:57121–57133. doi:10.18632/oncotarget.19078.
   PubMedGoogle Scholar
• Desmedt C, Salgado R, Fornili M, Pruneri G, Van Den Eynden G, Zoppoli G, Rothé F, Buisseret L, Garaud S, Willard-Gallo K, et al. Immune infiltration in invasive lobular breast cancer. J Natl Cancer Inst. 2018. doi:10.1093/jnci/djx268.
   Google Scholar
• Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, Rouas G, Francis P, Crown JPA, Hitre E, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31:860–867. doi:10.1200/JCO.2011.41.0902.
   PubMed Web of Science ®Google Scholar
• Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sorlie T, Warnberg F, Haakensen VD, Helland A, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109:2802–2807. doi:10.1073/pnas.1108781108.
   PubMed Web of Science ®Google Scholar
• Quigley D, Silwal-Pandit L, Dannenfelser R, Langerod A, Vollan HK, Vaske C, Siegel JU, Troyanskaya O, Chin S-F, Caldas C, et al. Lymphocyte invasion in IC10/basal-like breast tumors is associated with wild-type TP53. Mol Cancer Res. 2015;13:493–501. doi:10.1158/1541-7786.MCR-14-0387.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245.
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Singhal SK, Desmedt C, Haibe-Kains B, Criscitiello C, Andre F, Loi S, Piccart M, Michiels S, Sotiriou C. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol. 2012;30:1996–2004. doi:10.1200/JCO.2011.39.5624.
   PubMed Web of Science ®Google Scholar
• Ono M, Tsuda H, Shimizu C, Yamamoto S, Shibata T, Yamamoto H, Hirata T, Yonemori K, Ando M, Tamura K, et al. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2012;132:793–805. doi:10.1007/s10549-011-1554-7.
   PubMed Web of Science ®Google Scholar
• Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen international breast cancer conference 2015 in vienna: dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience. 2015;9:518. doi:10.3332/ecancer.2015.518.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Yamada Y, Narikiyo M, Ueno M, Tamaki H, Miki K, Wakatsuki KOHEI, Enomoto KOJI, Yokotani TOMOYO, Nakajima YOSHIYUKI. Prognostic significance of platelet-derived growth factor-BB expression in human esophageal squamous cell carcinomas. Anticancer Res. 2007;27:2409–2414.
   PubMed Web of Science ®Google Scholar
• Eide HA, Halvorsen AR, Sandhu V, Fane A, Berg J, Haakensen VD, Kure EH, Brustugun OT, Kiserud CE, Kyte JA, et al. Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. Clin Transl Immunol. 2016;5:e109. doi:10.1038/cti.2016.65.
   PubMed Web of Science ®Google Scholar
• Vincent L, Rafii S. Vascular frontiers without borders: multifaceted roles of platelet-derived growth factor (PDGF) in supporting postnatal angiogenesis and lymphangiogenesis. Cancer Cell. 2004;6:307–309. doi:10.1016/j.ccr.2004.09.024.
   PubMed Web of Science ®Google Scholar
• Dubey LK, Karempudi P, Luther SA, Ludewig B, Harris NL. Interactions between fibroblastic reticular cells and B cells promote mesenteric lymph node lymphangiogenesis. Nat Commun. 2017;8:367. doi:10.1038/s41467-017-00504-9.
   PubMed Web of Science ®Google Scholar
• Pietras K, Rubin K, Sjoblom T, Buchdunger E, Sjoquist M, Heldin CH, Östman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 2002;62:5476–5484.
   PubMed Web of Science ®Google Scholar
• Chen WC, Lai YH, Chen HY, Guo HR, Su IJ, Chen HH. Interleukin-17-producing cell infiltration in the breast cancer tumour microenvironment is a poor prognostic factor. Histopathology. 2013;63:225–233. doi:10.1111/his.12156.
   PubMed Web of Science ®Google Scholar
• Cochaud S, Giustiniani J, Thomas C, Laprevotte E, Garbar C, Savoye AM, Curé H, Mascaux C, Alberici G, Bonnefoy N, et al. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2. Sci Rep. 2013;3:3456. doi:10.1038/srep03456.
   PubMed Web of Science ®Google Scholar
• Roberts WK, Blachere NE, Frank MO, Dousmanis A, Ransohoff RM, Darnell RB. A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease. Ann Neurol. 2015;78:619–629. doi:10.1002/ana.24494.
   PubMed Web of Science ®Google Scholar
• Vazirinejad R, Ahmadi Z, Kazemi Arababadi M, Hassanshahi G, Kennedy D. The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis. Neuroimmunomodulation. 2014;21:322–330. doi:10.1159/000357780.
   PubMed Web of Science ®Google Scholar
• Monteagudo C, Martin JM, Jorda E, Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol. 2007;60:596–599. doi:10.1136/jcp.2005.032144.
   PubMed Web of Science ®Google Scholar
• Furuya M, Suyama T, Usui H, Kasuya Y, Nishiyama M, Tanaka N, Ishiwata I, Nagai Y, Shozu M, Kimura S. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Hum Pathol. 2007;38:1676–1687. doi:10.1016/j.humpath.2007.03.023.
   PubMed Web of Science ®Google Scholar
• Pellegrino A, Antonaci F, Russo F, Merchionne F, Ribatti D, Vacca A, Vaccaa A, Dammaccoa F. CXCR3-binding chemokines in multiple myeloma. Cancer Lett. 2004;207:221–227. doi:10.1016/j.canlet.2003.10.036.
   PubMed Web of Science ®Google Scholar
• Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood. 2000;95:627–632.
   PubMed Web of Science ®Google Scholar
• Lo BK, Yu M, Zloty D, Cowan B, Shapiro J, McElwee KJ. CXCR3/ligands are significantly involved in the tumorigenesis of basal cell carcinomas. Am J Pathol. 2010;176:2435–2446. doi:10.2353/ajpath.2010.081059.
   PubMed Web of Science ®Google Scholar
• Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14:e218–e228. doi:10.1016/S1470-2045(12)70582-X.
   PubMed Web of Science ®Google Scholar
• Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM. The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells. Clin Cancer Res. 2004;10:3091–3097. doi:10.1158/1078-0432.CCR-04-1002.
   PubMed Web of Science ®Google Scholar
• Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, et al. Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol. 2003;21:3469–3478. doi:10.1200/JCO.2003.02.009.
   PubMed Web of Science ®Google Scholar
• Stacklies W, Redestig H, Scholz M, Walther D, Selbig J. pcaMethods–a bioconductor package providing PCA methods for incomplete data. Bioinformatics. 2007;23:1164–1167. doi:10.1093/bioinformatics/btm069.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2018.
   Google Scholar
• Kolde R pheatmap: pretty Heatmaps. R package version 1.0.8. 2015.
   Google Scholar